Extracellular amino acid levels in the striatum of the dt(sz) mutant, a model of paroxysmal dystonia

The pathophysiology of idiopathic dystonia is still unknown, but it is regarded as a basal ganglia disorder. Previous studies indicated an involvement of a striatal GABAergic disinhibition and a cortico-striatal glutamatergic overactivity in the manifestation of stress-inducible dystonic episodes in the dt(sz) hamster, a model of idiopathic paroxysmal dystonia. These investigations were carried out postmortem or in anesthetized animals. In the present study, in vivo microdialysis in conscious, freely-moving dt(sz) and non-dystonic control hamsters was used to examine the levels of GABA, aspartate, glutamate, glutamine, glycine and taurine in each animal during following conditions: (1) at baseline in the absence of dystonia, (2) during an episode of paroxysmal dystonia precipitated by stressful stimuli, (3) during a recovery period and (4) at baseline after complete recovery. In comparison to non-dystonic controls, which were treated in the same manner as the dystonic animals, no differences could be detected under basal conditions. The induction of a dystonic episode in mutant hamsters led to higher contents of glycine in these animals in comparison to stressed but non-dystonic controls. Significant changes of glycine levels within the animal groups were not detected. The levels of the excitatory amino acids glutamate, glutamine and aspartate as well as the levels of the inhibitory amino acids GABA and taurine did not differ between the animal groups or between the periods of measurement. The higher levels of glycine might contribute to the manifestation of paroxysmal dystonia in dt(sz) hamsters, although unaltered glutamate, glutamine and aspartate levels do not support the hypothesis of a critical involvement of a cortico-striatal overactivity. It seems that a deficiency of GABAergic interneurons, found by previous immunohistochemical examinations, does not lead to reduced extracellular GABA levels in the striatum.

AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression

Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depressive disorder, but the nature of the disruption and the mechanisms by which it contributes to the syndrome are unclear. Glutamate can act via AMPA, NMDA, or metabotropic receptors. Using targeted mutagenesis, we demonstrate here that mice with deletion of the main AMPA receptor subunit GluR-A represent a depression model with good face and construct validity, showing behavioral and neurochemical features of depression also postulated for human patients. GluR-A(-/-) mice display increased learned helplessness, decreased serotonin and norepinephrine levels, and disturbed glutamate homeostasis with increased glutamate levels and increased NMDA receptor expression. These results correspond well with current concepts regarding the role of AMPA and NMDA receptors in depression, postulating that compounds that augment AMPA receptor signaling or decrease NMDA receptor functions have antidepressant effects. GluR-A(-/-) mice represent a model to investigate the pathophysiology underlying the depressive phenotype and to identify changes in neural plasticity and resilience evoked by the genetic alterations in glutamatergic function. Furthermore, GluR-A(-/-) mice may be a valuable tool to study biological mechanisms of AMPA receptor modulators and the efficacy of NMDA antagonists in reducing behavioral or biochemical changes that correlate with increased helplessness.

Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety

The behaviour of animals in tests of anxiety varies between strains, even in identical tests and surroundings. To evaluate the results obtained, a more detailed knowledge of the behaviour of different rat strains is indispensable. Identically raised Fischer 344 rats and two stocks of Wistar rats were examined in two animal tests of anxiety: the X-maze and a modified open-field test following diazepam treatment (0.5-4.0 mg/kg). Harlan-Wistar rats were the least 'anxious' when the behaviour of vehicle treated controls was compared. The largest effect of the anxiolytic diazepam, however, was observed in Harlan-Fischer rats. To determine possible reasons for strain and stock differences, plasma concentrations of diazepam and metabolites and concentrations of serotonin (5-HT) in the CNS were measured. Plasma concentrations of diazepam and metabolites differed between the strains with the Harlan-Fischer rats showing higher diazepam concentrations. 5-HT levels in discrete brain regions varied with Harlan-Fischer rats having higher 5-HT concentrations. Strain differences influence the anxiety-associated behaviour of untreated animals and the effect of anxiolytics.

Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats

Deep brain stimulation of the subthalamic nucleus is an established therapeutic strategy for patients with Parkinson's disease. Although the exact mechanisms of action remain unknown, it is noteworthy that dopaminergic medication can be markedly reduced after neurostimulation of the subthalamic nucleus. Previously, we have shown that deep brain stimulation of the subthalamic nucleus is followed by an increase of striatal extracellular dopamine metabolites in naive rats. In the present study we examined the effects of deep brain stimulation on striatal monoamine metabolism in the intrastriatal 6-hydroxydopamine rat model of Parkinson's disease. Deep brain stimulation of the subthalamic nucleus was followed by a delayed increase of extracellular 3,4-dihydroxyphenylacetic and homovanillic whereas dopamine levels were unchanged in stimulated rats and controls. Our results indicate that deep brain stimulation of the subthalamic nucleus affects significantly striatal dopaminergic metabolism in 6-hydroxydopamine lesioned rats.

The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat

Deep brain stimulation of the globus pallidus internus has been recently shown to alleviate parkinsonian symptoms and levodopa-induced dyskinesias. However, its exact mechanisms of action are unclear. Pallidal neurones are connected via various pathways to the dopaminergic nigrostriatal system. In the present study we investigated the hypothesis that deep brain stimulation of the entopeduncular nucleus (corresponds to the human internal pallidum) affects striatal dopaminergic metabolism in naive and 6-hydroxydopamine (6-OHDA) lesioned rats using microdialysis. Our results show that stimulation of the entopeduncular nucleus does not significantly affect striatal dopamine metabolism (of dopamine, 3, 4-dihdroxyphenylacetic acid and homovanillic acid) in naive and 6-OHDA-lesioned animals. They contrast with our previous observations that deep brain stimulation of the subthalamic nucleus increases striatal dopamine metabolism suggesting differential effects of these nuclei on striatal dopamine metabolism.

Comparison by microdialysis of striatal L-DOPA after its systemic administration in rats with probes implanted acutely or through a guide cannula

Different methods of microdialysis probe implantation are utilized according to the purpose and needs of each particular study. However, very few experiments have systematically examined whether these different techniques have an impact on the obtained data. In the present study we examined the influence of two different microdialysis methods - acute probe implantation vs. insertion into a preimplanted guide cannula - on the striatal extracellular availability of systemically administered L-DOPA. Furthermore, we monitored the effects of L-DOPA administration on dopamine and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC). In rats that received a guide cannula 4 days prior to probe insertion and microdialysis, extracellular L-DOPA concentrations increased to concentrations that were about nine times higher than in rats with acute implantation of a microdialysis probe. Extracellular DOPAC concentrations were also higher in the chronic preparations but dopamine concentrations showed no differences between groups. Our results suggest that the observed differences may be due to inflammatory disruption of the BBB following chronic implantation of a guide cannula.

High frequency stimulation of the subthalamic nucleus influences striatal dopaminergic metabolism in the naive rat

High frequency stimulation (HFS) of the subthalamic nucleus (STN) can partially alleviate motor symptoms in patients with Parkinson's disease (PD). However, the mechanism of action of HFS is incompletely understood. We investigated the effect of HFS (130 Hz) and low frequency stimulation (LFS, 20 Hz) of the STN on striatal dopaminergic transmission and metabolism using in vivo microdialysis in anaesthetized and freely moving rats. While LFS had no effect, HFS of the STN produced a delayed, stable and intensity-dependent increase of extracellular dopamine metabolites. Striatal extracellular levels of dopamine and 5-HIAA were not influenced by HFS or LFS in the present experimental paradigm. We conclude that HFS of the STN influences striatal dopaminergic metabolism in naive, nonlesioned rats.

Feeding and 8-OH-DPAT-related release of serotonin in the rat lateral hypothalamus

Based on the different effects of somatodendritic 5-HT1A agonist 8-OH-DPAT on food intake whether given to food-deprived rats or freely feeding rats, we hypothesized that the effects of 8-OH-DPAT on extracellular serotonin (5-HT) in the lateral hypothalamus (LH) will interfere with different feeding states, eventually resulting in different patterns of 5-HT release. In a microdialysis study we measured extracellular 5-HT in the LH after 8-OH-DPAT under four experimental conditions, i.e., in freely feeding rats with no food available, freely feeding rats with access to food, in food-deprived rats with no food available, and in food-deprived rats with good available after treatment. The results show a significant decrease of 5-HT release after 300 microg/kg 8-OH-DPAT (i.p.) in freely feeding rats. This effect is not seen when food is provided after drug treatment. In contrast, the same dose of 8-OH-DPAT has no effect on 5-HT release in food-deprived rats. In addition, providing food after drug treatment does not change the release pattern significantly in food-deprived rats, suggesting more complexity in the underlying mechanisms. The present study describes the effects of 8-OH-DPAT on 5-HT release in the LH, depending on feeding conditions and feeding-related behavioral states.

Hippocampal 5-HT and NE release in the transgenic rat TGR(mREN2)27 related to behavior on the elevated plus maze

The transgenic rat TGR(mREN2)27 was generated to study mechanisms involved in the hypertensive process. A characteristic of this rat is a high expression of the murine renin-2 gene in several peripheral tissues and in the brain. The high expression of the transgene is associated with increased local formation of angiotensin II. In a previous study, we studied for the first time the behavior of male TGR(mREN2)27 rat in the open field and on the elevated plus maze. There were no differences between TGR(mREN2)27 and SPRD-controls in locomotor activity measured in the open field. While placed on the elevated plus maze, however, the TGR(mREN2)27 rats showed a greater "anxiogenic" profile than the SPRD-rats. The present study was aimed to characterize neurotransmitter release involved in anxiety in hippocampus of TGR(mREN2)27 rats during exposure to the elevated plus maze. Exposure to the maze resulted in an increased intrahippocampal serotonin release with the same maximum both in the transgenic rats and in the control rats. However, the subsequent decrease was significantly faster in the TGR(mREN2)27 compared to the SPRD-controls. The latter suggests that the serotonergic system is functionally changed in the TGR(mREN2) rat, too. In contrast, norepinephrine release did not change during exposure to the maze and there were no significant differences in norepinephrine release between transgenics and controls.

CCK-8S facilitates 5-HT release in the rat hypothalamus

The effects of the neurotransmitter serotonin (5-HT) and the neuropeptide cholecystokinin (CCK) on food intake are well established. Based on pharmacological studies, an interactive model for 5-HT and CCK was proposed. The present microdialysis study was aimed to provide neurochemical evidence for a facilitatory effect of CCK-8S on 5-HT release in the lateral hypothalamus under in vivo conditions. The results indicate an increase of extracellular hypothalamic 5-HT both during food intake in previously food-deprived rats and also after systemic administration of 8 microg/kg and 40 microg/kg CCK-8s in food-deprived rats. The results show that peripherally administered CCK-8s induces central serotonergic effects, possibly related to feeding.

Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors

Anticancer drugs reversibly bound to magnetic fluids (ferrofluids) could be concentrated in locally advanced tumors by magnetic fields that are arranged at the tumor surface outside of the organism. If certain requirements are met, systemic toxicity might be minimized, and local tumor efficacy might be increased. We have conducted a Phase I clinical trial using this approach in patients with advanced and unsuccessfully pretreated cancers or sarcomas. Nine such patients received two treatment courses, 3 patients received one course, and 2 patients received three courses of magnetic drug targeting consisting of the infusion of epirubicin in increasing doses (from 5 to 100 mg/m2) that had been chemically bound to a magnetic fluid and the application of magnetic fields to the tumors for 60-120 min. In 2 of 14 patients, the same dose of epirubicin not bound to a magnetic fluid was administered systemically 3 weeks after drug targeting for intraindividual comparisons. Magnetic drug targeting with epirubicin was well tolerated. In one case, a planned second treatment was withdrawn, because of an episode of chills 130 min after infusion of the magnetic drug. Two patients received a third treatment because of good responses after the first two therapies. Based on magnetic resonance tomographic techniques, pharmacokinetics, and the histological detection of magnetites, it was shown that the ferrofluid could be successfully directed to the tumors in about one-half of the patients. Organ toxicity did not increase with the treatment, but epirubicin-associated toxicity appeared at doses greater than 50 mg/m2. Although treatment with magnetic drug targeting seems safe, improvements are necessary to make it more effective and independent of patient- or disease-related problems. A study design to compare conventional treatments with the new treatment form within one patient seems crucial to eliminate interindividual differences.

Time course and role of extracellular Ca2+ in veratridine-induced glutamate release

The veratridine-induced release of glutamate in the striatum of anaesthetized rats was studied using regional brain microdialysis to elucidate the role of extracellular Ca2+ and to investigate the exact time course of the glutamate response. In a first series of experiments with Ca(2+)-depletion starting simultaneously with the veratridine pulse no significant differences were found under Ca(2+)-replete and Ca(2+)-free conditions. Strikingly, under both conditions glutamate efflux followed a biphasic time course. When Ca2+ depletion preceded veratridine stimulation a significant inhibition of the initial glutamate release was found, indicating that the first glutamate portion originates from Ca(2+)-dependent vesicular exocytosis. The nature of the second and longer lasting phase of glutamate efflux is not clear, but it may be mediated by reversal of the glutamate uptake system of the plasma membrane located both on neurones and on astrocytes. This points to a possibly important contribution of glial cells to glutamate overflow under pathological conditions and should be subject to further investigations.

Circadian rhythms of dopamine and cholecystokinin in nucleus accumbens and striatum of rats--influence on dopaminergic stimulation

The concentrations of cholecystokinin (CCK) and dopamine (DA) were determined in the nucleus accumbens (anterior, posterior) and striatum of rats every 2 h during a period of 24 h. For both substances, a circadian rhythm was found, which was best fitted by a dominant 24-h period superimposed by the second (12 h) and fourth (6 h) harmonics. The rhythms in CCK and DA were negatively correlated because of a difference in phase position by approximately 3 h. A dominant DA peak was found in the light phase coinciding with a trough in CCK and vice versa in the dark phase. Based on these data, CCK and DA were determined in rats treated with gamma-butyrolactone (GBL; inhibitor of DA release) or thyrotropin-releasing hormone (TRH; stimulator of DA release) at 0900 h or 1300 h to study a putative time-dependency in drug effects. After GBL treatment, CCK as well as DA increased by up to 200% whereas TRH administration led to a rather complex alteration, inasmuch as CCK was increased or decreased, depending on circadian time, whereas the rhythmic pattern in DA remained relatively unaffected. Comparing the drug effects obtained at 0900 h with the response seen at 1300 h revealed significant quantitative as well as qualitative differences. The results demonstrate that the neurotransmission system investigated changed its level of activity depending on time of day. No changes were obtained that convincingly may be ascribed to colocalization of DA and CCK. It is concluded that the chronobiological data indicate a close interaction of CCK and DA in various areas of the rat brain, independent of colocalization.

3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats

The underlying cause of long-term complications of L-DOPA therapy in Parkinson's disease is largely unknown. Recently, centrally and peripherally acting catechol-O-methyltransferase (COMT) inhibitors became available. These drugs are capable of inhibiting the generation of 3-O-methyl-DOPA (3-OMD), a major metabolite of L-dopa developing considerable plasma levels during L-dopa therapy. The use of these drugs offers the opportunity to study the involvement of 3-OMD in the development of behavioral supersensitivity following repeated doses of L-dopa over 11 days in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal dopaminergic system. Repeated daily administration of L-dopa/Carbidopa produced continuous increase of contralateral rotations to both L-dopa/Carbidopa and to challenge doses of apomorphine. This increase was not influenced by peripherally and peripherally plus centrally acting COMT inhibitors, OR-462 and OR-486, respectively, administered simultaneously with L-dopa/Carbidopa. Both COMT inhibitors suppressed the L-dopa induced increase of 3-OMD plasma levels, OR-486 being more effective than OR-462. This indicates that 3-OMD is not involved in the development of behavioral supersensitivity following repeated L-dopa treatment in rats with unilateral 6-OHDA lesion of the nigrostriatal system.

Binding of cholecystokinin-8 (CCK-8) peptide derivatives to CCKA and CCKB receptors

The structural requirements for the selective binding of cholecystokinin-8 (CCK-8)-related peptides to peripheral (CCKA) receptors are not sufficiently understood. In this study, the interaction of a series of newly shortened analogues of CCK-8 with both receptor subtypes was analyzed by displacement studies using [3H]-CCK-8 and 125I-Bolton-Hunter (BH)-CCK-8 as radioligands. The pentapeptide derivative of CCK-8, succinyl-Tyr (SO3H)-Met-Gly-Trp-Met-phenethylamide, was found to bind selectively with high affinity to the CCKA receptor. The replacement of Met28 and/or Met31 by norleucine and of L-Trp30 by its D-analogue had no significant effect on the binding properties of the peptide. Further C-terminal shortening resulted in a drastic loss of affinity and selectivity of the CCK receptor binding.

Correlative circadian rhythms of cholecystokinin and dopamine content in nucleus accumbens and striatum of rat brain

Due to contrary results concerning the interaction of cholecystokinin and dopamine (CCK/DA) circadian variations in CCK/DA concentration were investigated in forebrain nuclei of rats (Nc. accumbens, striatum) in order to assess the influence of time of day on neurotransmission. CCK was determined by a radioimmunoassay, DA was measured by electrochemical detection after HPLC separation. A distinct circadian rhythm, superimposed by harmonics (12 h, 6 h) was found in the content of both DA and CCK. A trough was shown for CCK during the light phase and a crest during the late afternoon and the dark phase, respectively. For DA the opposite was found. Caused by a phase-shift of about 3-4 h, the CCK/DA rhythms are negatively correlated. The differences are significant at 11.00 h, 13.00 h, 21.00 h, and 03.00 h. The results indicate that circadian processes are involved in neuronal transmission of CCK and DA.

Effect of tertiary amine on the carbodiimide-mediated peptide synthesis

The effect of tertiary amine (DIEA) on reaction rate and product purity of a carbodiimide/HOBt-mediated peptide synthesis was studied. It was found that very rapid activation can be achieved using carbodiimide/HOBt in non-polar solvents, such as DCM. Although the HOBt is poorly soluble in DCM, the activation proceeds within 2 min, probably forming the HOBt-ester. By such a preactivation followed by a coupling in the presence of DIEA the rate of coupling is comparable with other rapid methods using BOP or TBTU, and no racemization was found in a model coupling (less than 0.1%). For comparison, syntheses of neurotensin by means of different coupling reagents (BOP, TBTU, OPfp-esters) and the DIEA-catalyzed coupling after carbodiimide/HOBt-activation under comparable conditions have shown that these procedures are of the same value in view of coupling efficiency and product purity.

[Synthesis of a potential metabolite of the carcinostatic bendamustin (Cytostasen)]

The synthesis of the methylester of (5-[Bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl-(2))ethanolic acid (4) has been described. The assumption that the butanoic acid group of the anticancer drug bendamustine (Cytostasan) will be biotransformed in patients to the ethanoic acid group as found for chlorambucil has been disproved by means of a comparison of the methylated metabolites and 4 by MS and HPLC.

Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites

Four tumor patients with a normal liver function were each given twice 30 mg/m2 adriamycin (ADR) and then once 70 mg/m2 ADR in the form of 3-min intravenous bolus injections at three-week intervals. In addition to the first and third ADR administrations, the patients were each given p.o. 875 mg of antipyrine. During the six-week study period, the kinetics of antipyrine displayed a high degree of intra-individual constancy. Its CL varied between 75 and 119 percent intra-individually. The kinetic parameters of CL, AUC/dose, VDss, MRT and t1/2 gamma of ADR did not differ between dosages of 30 and 70 mg/m2. The ADR-dose-standardized AUC10-40 min of adriamycinol (ADR-OH), its concentration time product at the times of its highest concentration in plasma, did not display any dependence upon the ADR dose. The AUCADR-OH/dose quotient, however, was found to be significantly higher (p less than 0.05) at 70 mg/m2 than at 30 mg/m2. The MTR and the t1/2z of ADR-OH showed a trend towards prolongation at 70 mg/m2. The ADR-dose-standardized AUC of the aglycones showed no dependence upon the ADR dose while the ADR-dose-standardized AUC10-40 min of the aglycones was significantly lower at a high ADR dose (p less than 0.05) than at a small ADR dose. The results suggest that in the ADR dose range studied the ADR pharmacokinetics is dose-independent and linear, and the rate at which ADR-OH, its main metabolite is formed, is also dose-independent. In contrast, the elimination of ADR-OH seems to be capacity-limited.(ABSTRACT TRUNCATED AT 250 WORDS)

Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver

The pharmacokinetics of adriamycin, its metabolite adriamycinol, and antipyrine were studied in 17 patients with moderate tumor involvement of the liver and compared to that of 19 tumor patients with normal liver function (Preiss et al. 1985). The individual liver function parameters deviated from normal by a factor ranging from 2.5 to 12.2. The t1/2 alpha and t1/2 beta, the AUC (corrected for body weight and dose) and the total body clearance (CL, corrected for body weight) of adriamycin did not differ significantly between the two groups of patients. Likewise, there was no difference in the kinetic parameters of antipyrine between the two groups. Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver. The CL, the AUC, and t1/2 beta of adriamycin correlated significantly (P less than 0.001 and P less than 0.01) with the corresponding kinetic parameters of antipyrine, but not with the usual liver function parameters. No correlation could be found between the kinetic parameters of adriamycinol and those of antipyrine.

[The pharmacokinetics of bendamustine (Cytostasane) in humans]

The pharmacokinetics of bendamustine (Cytostasane) was determined in plasma on seven patients after its intravenously and oral application, respectively. Cytostasane was given in a dosis of 4.2-5.5 mg . kg-1 as an intravenous infusion over 3 min and as gelatine capsules in a 7-d intervall. Its elimination from the plasma is fast, monoexponentially and two-phasic after intravenous application (t1/2 alpha = 9.6 min, t1/2 beta = 36.1 min). The AUC was 11.17 micrograms . ml-1 . h, the central distribution volume 11.15 l and the distribution volume in steady state 20.51 l. The mean total clearance was 528.9 ml . min-1. After oral application maximal plasma levels of Cytostasane were detectable before 1 h. The mean oral bioavailability was 0.57, ranged from 0.25 to 0.94. Cytostasane undergoes metabolism. Its hydrolysis in plasma is slow (t1/2 = 1.67 h). After Cytostasane the depression of leucocytes was mild.

Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects

After a simultaneous administration of adriamycin and antipyrine to 19 tumor patients, the plasma kinetics of both drugs, the therapeutic effect and the reaction to white blood cells were determined. Antipyrine was given orally at a dose of 875 mg, whereas adriamycin was administered by means of intravenous infusion for 20 min at 60 mg/m2. This application was repeated in eight patients after three weeks. Nine patients had a normal liver function. In ten patients, slight increases were found in individual liver function parameters. All patients were free from metastases of the liver and had bilirubin levels within the normal range. Antipyrine followed an open one-compartment model, whereas adriamycin followed an open two-compartment model. In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min. For antipyrine and adriamycin, these parameters varied interindividually by the factors 2.8 and 3.1, respectively. No correlations were found between the liver function parameters, and the kinetic elimination parameters and the areas under the curves of both drugs. However, significant positive correlations were found to exist between t1/2 el antipyrine and t1/2 beta adriamycin and between the areas under the curves of the two drugs. A relationship between the AUC adriamycinol/AUC adriamycin ratio (which was 0.52 in the mean) and the antipyrine elimination rate did not exist. As compared to 12 persons with no response or progression, the seven patients with partial or complete response had a significantly higher AUC and a significantly lower Cl tot of adriamycin. As compared to the patients with elimination half-life values of less than 20 h, five patients with antipyrine elimination half-life values of more than 20 h had a significantly longer adriamycin elimination beta-phase and a stronger depressive effect on the white blood cells. The results obtained suggest that the antipyrine kinetics in patients with normal or slightly impaired liver function is a useful parameter for an assessment of the depression of white blood cells and the dose adjustment for adriamycin.

[Bioavailability of cyclophosphamide following oral administration in high doses]

Mean rate of absorption of cyclophosphamide after oral administration from studies in which the drug is given in doses of 0,7 g/m2 body surface both orally and intravenously to the same 18 tumor patients is 87.7% (s - 21.1%). The drug may be administered orally with good bioavailability at the high dose.

[Methodology of the colorimetric determination of alkylating cytostatics with 4-(4'-nitrobenzyl)pyridine (NBP) in plasma]

The sensitivity of the colorimetric determination of alkylating cytostatics with 4-(4'-nitrobenzyl)pyridine (NBP) has been increased by modifying procedures described in the literature. This increase in sensitivity was accomplished as follows: --Precipitation of protein with absolute ethanol at degree C; --reduction of the sample volume by evaporating the ethanol extract in a nitrogen flow; --control of the optimum pH value by means of a micro-glass electrode; --meticulously timed working under cooling in a dimmed room. The total alkylating activity and the part of endogenously activated cyclophosphamide were determined in four patients.

Sodium flux and lipid spectrum in the erythrocyte membrane in essential hypertension

In the erythrocyte membranes of normotensive individuals and patients with essential hypertension, sodium flux behavior, cholesterol content, phospholipid spectrum, and the fatty acid composition of the phospholipids were measured. There was no difference between normotensives and hypertensives in sodium influx in the erythrocyte. In both groups, 1 microM norepinephrine resulted in a significantly equal increase of sodium influx after an incubation period of 15 min. Compared with normotensives, erythrocytes in essential hypertensive patients showed a decreased sodium efflux. The cholesterol/phospholipid quotient of the erythrocyte membrane of hypertensive subjects increased in comparison with that of normotensive individuals. No differences between the two groups were found in the phospholipid pattern and in the fatty acid composition of phosphatidylserine/-inositol, -choline, and sphingomyelin. However, in phosphatidylethanolamine of the erythrocyte membrane in essential hypertensives in contrast to normals, a decreased content of the fatty acid fraction 22:0/20:3 and in increased content of the fatty acid fraction of 20:5/22:2/22:3 was found. The dependence of the Na turnover on the lipid spectrum of the erythrocyte membrane is discussed. The altered lipid composition of the erythrocyte membrane in essential hypertensives does not seem to cause the altered Na efflux behavior.